4yr
Reasonable Timing of Radiotherapy for Stage IV Non-Small-Cell Lung Cancer During Targeted Therapy Based on Tumour Volume Change - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34631535/
doi: 10.3389/fonc.2021.705303. 1 Department of Oncology, Affiliated Hospital of Guizhou Medical University, Guiyang, China. 2 Department of Oncology, Guizhou Cancer Hospital, Guiyang, China. 3 Department of Oncology, Guiyang Guihang Hospital, Guiyang, China. doi: 10.3389/fonc.2021.705303. 1 Department of Oncology, Affiliated Hospital of Guizhou Medical University, Guiyang, China.
• Source: Frontiers in Oncology
• Conclusion/Relevance: “To obtain a high radiation dose and control radiation toxicity, the 40th day after targeted therapy may be a reasonable time to start radiotherapy for stage IV NSCLC with EGFR-positive mutations.”
• In the current study, researchers aimed to elucidate reasonable timing of radiotherapy for stage IV NSCLC harboring EGFR-positive mutations during targeted therapy based on tumor volume change. Measurements were taken every 10 days in 27 patients.
• Following treatment, primary tumors shrunk in all patients, but the rate/speed was inconsistent. Tumor volume noticeably shrunk within 40 days and was significantly different every 10 days. Average tumor volume slowly reduced and stabilized after 40 days.
• “Increasing the radiotherapy dose to the primary tumour was strongly associated with improved OS, and a radical radiation dose may be more beneficial for OS, especially in patients with oligometastases,” wrote the authors.